MedTrace Logo

CoolLoop Paroxysmal Atrial Fibrillation

NCT02553239 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2019-03-15

No results posted yet for this study

Summary

This clinical investigation evaluates the safety of cryoablation (sclerotherapy of muscle tissue of the heart by freezing) in paroxysmal atrial fibrillation with the newly developed CoolLoop® cryoablation catheter.

A further aim of the investigation is the evaluation of the efficacy and average duration of the applied procedure.

Conditions

  • Atrial Fibrillation (Paroxysmal)
  • Arrhythmias, Cardiac
  • Cardiovascular Diseases
  • Heart Diseases
  • Pathologic Processes

Interventions

DEVICE

CoolLoop®

Cryoablation of Atrial Fibrillation Using the CoolLoop Cryoablation System

Sponsors & Collaborators

  • Accovion GmbH

    collaborator INDUSTRY

  • afreeze GmbH

    lead OTHER

Principal Investigators

  • Karoline Etschmaier, PhD · afreeze GmbH

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-07-31
Primary Completion
2019-02-14
Completion
2019-02-14

Countries

  • Austria
  • Germany
  • Switzerland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02553239 on ClinicalTrials.gov